BD Launches Combination Test for COVID-19 and Influenza A/B

Becton, Dickinson and Company (BD Franklin Lakes, NJ, USA) has launched a new high-throughput molecular diagnostic combination test for SARS-CoV-2 and Influenza A/B, which is available for the BD COR PX/MX System in countries accepting the CE mark.

The BD SARS-CoV-2/Flu assay for the BD COR System is an automated multiplexed real-time RT-PCR test to detect and differentiate SARS-CoV-2 and influenza A, and/or influenza B from a single nasal sample from patients who are showing signs of respiratory viral infection, as well as those who are asymptomatic. The BD COR MX instrument will perform the analytical steps of the BD SARS-CoV-2/Flu molecular assay, including extraction, amplification and detection.

The BD COR MX instrument was launched in 2021 with the BD CTGCTV2 molecular assay, a single test that detects the three most prevalent non-viral sexually transmitted infections (STIs) - Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC) and Trichomonas vaginalis (TV). The system integrates and automates the complete molecular laboratory workflow from sample processing to diagnostic test result. The BD COR PX instrument focuses on sample workflow for diagnostic specimens and assays, preparing the samples by performing the appropriate pre-analytical processing steps and automatically delivering the samples to the BD COR MX instrument for molecular analysis.

The BD COR MX/PX System allows 1,700 specimens to be loaded, with onboard capacity for reagents and samples that provide more than six hours of unimpeded system processing and up to 1,000 sample results in 24 hours, eliminating multiple technologist interactions currently required per shift. The system is modular and scalable, and designed to address multiple needs within laboratories for expanding molecular testing and increasing test volumes. The BD COR System is particularly well-suited to laboratories requiring high throughput for sample results, minimizing staff interactions and automating labor-intensive and error-prone manual processes.

“As long as the COVID-19 pandemic persists or evolves to an endemic situation, testing for the virus will remain an important public health tool,” said Celine Roger-Dalbert, vice president diagnostic assays R&D at BD. “And while last year’s flu season was relatively tame, with many areas loosening guidelines and mask guidance, this season could see a resurgence in seasonal illnesses. It is important to quickly diagnose if a patient has COVID-19 or flu, and type of flu, to inform patient management and to treat appropriately and early in the course of the disease.”

Related Links:
Becton, Dickinson and Company 

Visit expo >

Gold Member

SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test

SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)

Verification Panels for Assay Development & QC
Seroconversion Panels

New

Mycoplasma Pneumoniae Virus Test

Mycoplasma Pneumoniae Virus Detection Kit

New

Centromere B Assay

Centromere B Test